Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Period	Net Profit Margin
2022-12-31	N/A
2023-12-31	-2204.65%
2024-12-31	-67359.14%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CNTA	$39.47	-0.20%	2.87M
3
4
5

Centessa Pharmaceuticals plc (CNTA) Profit Margin

Profit Margin Data

Get Centessa Pharmaceuticals plc Data in Excel

More CNTA Financial Data